Jove, J
4114  Ergebnisse:
Personensuche X
?
2

Should dual antiplatelet therapy be maintained beyond one y..:

Blin, P ; Danchin, N ; Benichou, J...
European Heart Journal.  43 (2022)  Supplement_2 - p. , 2022
 
?
 
?
5

Saving time in the radiotherapy procedures for COVID-19 pne..:

Bonet, M. ; Vázquez, S. ; García, E....
Clinical and Translational Oncology.  23 (2021)  11 - p. 2344-2349 , 2021
 
?
7

Changes in therapeutic strategy in metastatic castration re..:

Thurin, N. ; Rouyer, M. ; Jové, J....
European Urology Open Science.  19 (2020)  - p. e901 , 2020
 
?
9

Age, Gleason Score, and PSA are important prognostic factor..:

Valero, J. ; Peleteiro, P. ; Henríquez, I....
Clinical and Translational Oncology.  22 (2020)  8 - p. 1378-1389 , 2020
 
?
10

Survival after biochemical failure in prostate cancer treat..:

González-San Segundo, C. ; Jové, J. ; Zapatero, A....
Clinical and Translational Oncology.  21 (2019)  8 - p. 1044-1051 , 2019
 
?
11

P1664Pharmacological treatment patterns in heart failure: a..:

Bosco-Levy, P ; Favary, C ; Jove, J...
European Heart Journal.  40 (2019)  Supplement_1 - p. , 2019
 
?
14

Identifying patients with metastatic Castration-Resistant P..:

Thurin, N. ; Rouyer, M. ; Jové, J....
European Urology Supplements.  17 (2018)  14 - p. e2912 , 2018
 
?
15

Risk factors for the primary effectiveness endpoint in seco..:

Danchin, N. ; Blin, P. ; Falissard, B....
Archives of Cardiovascular Diseases Supplements.  10 (2018)  1 - p. 9 , 2018
 
1-15